Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648724 · ClinicalTrials.gov registry record · Phase 1
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
A Phase 1 study, sponsored by Symphogen A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT02648724: Completed Phase 1 study, sponsored by Symphogen A/S.
NCT02648724 is a Phase 1 study that has completed, run by Symphogen A/S. The registered enrollment target is 57 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02648724, a Phase 1 study, has completed, sponsored by Symphogen A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.
Primary Outcome
The primary objective of Part 1 was to assess the safety and tolerability of Sym015 on a Q2W schedule. This was assessed by evaluating the occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of Sym015 administration. Q2W = every second week.
Interventions
- DRUG Sym015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-12 |
| Phase | Phase 1 |
What the finished NCT02648724 record still lists
NCT02648724 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Sym015 is the first listed.
NCT02648724 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02648724 about?
NCT02648724 is a clinical study titled "Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies". This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.
What is the current status of trial NCT02648724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2016-03. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02648724?
The interventions under investigation include: Sym015 (DRUG).
Who is sponsoring clinical trial NCT02648724?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02648724's enrollment target sits among peer trials
57 901st of 2000 higher than 1,099 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia